KeyWEn.com  
 
 
 
Median Follow-Up       Article     History   Tree Map
  Encyclopedia of Keywords > Time > Calendars > Months > Median Follow-Up   Michael Charnine

Keywords and Sections
MEDIAN FOLLOW-UP DURATION
MEDIAN FOLLOW-UP PERIOD
MEDIAN FOLLOW-UP TIME
REMAINING
DEATHS
LONG-TERM SURVIVAL
MEDIAN SURVIVAL
RESULTS
SEVENTEEN PATIENTS
RELAPSED
SURVIVAL
YEARS
RECURRENCE
TUMOR RECURRENCE
MEDIAN AGE
RANGE
TRANSPLANTATION
RELAPSE
PATIENTS
MONTHS
MEDIAN FOLLOW-UP
Review of Short Phrases and Links

    This Review contains major "Median Follow-Up"- related terms, short phrases and links grouped together in the form of Encyclopedia article.

Definitions

  1. Median follow-up was 31 months for the 195 patients who survived (range, 3-49 months).

Median Follow-Up Duration

  1. New cardiac events were observed in 28 of 79 patients (35%) after a median follow-up duration of 3.5 years (range 2.7 to 7.3).

Median Follow-Up Period

  1. The median follow-up period of these patients was 20 months (2-33 months).

Median Follow-Up Time

  1. The median follow-up time was 76 weeks (range 2–296 weeks) for the entire group of patients.
  2. Updated means of all lipid profile indices were calculated after a median follow-up time of 9.8 years.

Remaining

  1. The remaining 4 patients in whom no etiology was identified had no clinical or radiologic evidence of cholelithiasis at a median follow-up of 22 months.

Deaths

  1. Secondly, with a median follow-up of almost 10 years, we were able to observe a substantial number of deaths to base our conclusions on.

Long-Term Survival

  1. Long-term survival, quality of life and weigh gain were identical after median follow-up of 63 (range 4-93) months.

Median Survival

  1. Median survival was 11 months (median follow-up, 93 months).

Results

  1. Results: the median follow-up was 50 months.

Seventeen Patients

  1. Seventeen patients are alive at a median follow-up of 57 months (range, 6 to 121 months).

Relapsed

  1. At a median follow-up of 15 months, 9 patients (26%) relapsed.

Survival

  1. Patients had a median follow-up of 39 months and 79% of the patients were followed at least 12 months for survival and selected adverse events.
  2. The Kaplan-Meier estimate of survival was 83.9% (95% CI, 70.1-95.2%) with a median follow-up duration of 33.5 (6-44) months.

Years

  1. A, Overall survival of 122 patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine; median follow-up was 7.2 years.
  2. A benign biologic behavior has been suggested based on the absence of recurrences with a median follow-up of 3 years.
  3. As of 1 June 1991, 14 patients are alive and in remission at a median follow-up of 1.9 years (range 1.5-3.3); all except one have normal performance scores.

Recurrence

  1. After a median follow-up of 27 months, all 18 patients who underwent laparoscopic lymphadenectomy survived without any evidence of recurrence or metastasis.

Tumor Recurrence

  1. All five patients are currently alive without evidence of tumor recurrence after a median follow-up of 43 months.

Median Age

  1. RESULTS: A total of 322 patients were studied (median age, 54 years; median follow-up, 13.6 years).

Range

  1. RESULTS: Seventy-seven patients were assigned to atorvastatin and 78 to placebo, with a median follow-up of 25 months (range, 7 to 36).
  2. The 6 remaining patients are alive and in continuous complete remission, with a median follow-up of 10.8 years (range, 7.3 to 17.8 years).
  3. The median follow-up of infected patients was 11.5 months (range, 3-18 months; Table 3).

Transplantation

  1. At a median follow-up of 1.1 years, combination prophylaxis with lamivudine and HBIG prevented hepatitis B recurrence following liver transplantation.

Relapse

  1. During median follow-up of 1 year no relapse of MALT lymphoma occurred.
  2. Within a median follow-up period of 24 months, no relapse of the lymphoma or reinfection with H. heilmannii occurred.

Patients

  1. RESULTS: Three (7%) patients died and 3 (7%) patients underwent heart transplantation during a median follow-up of 8.6 years.
  2. The median length of treatment for all patients was 35 weeks (range, 0.4 to 56), and the median follow-up was 50 weeks (range, 1 to 77).
  3. The median follow-up of patients who survived without relapse is 6.9 years (3.1–16.8 years).

Months

  1. All patients had a minimum of 16 months of treatment or discontinued early; the median follow-up was 18 months.
  2. Follow-up was completed in all 100 patients, with a median follow-up of 24 months.
  3. The median follow-up after liver transplantation was 118 months (range 16-187 months) and after recurrence 30 months (range 4-79 months).

Median Follow-Up

  1. Patients were seen every 3 months and the median follow-up was 3.4 years (range 0.3 to 6.1 years).
  2. At a median follow-up of 5 years (0, 13-12 years), we found a higher incidence of TE after transplantation in patients with "acquired" APCR (16.7% vs.
  3. The median age was 10 years and the median follow-up after initiation of tegaserod treatment was 11.3 months (range 2.3-45.2 months).

Categories

  1. Encyclopedia of Keywords > Time > Calendars > Months
  2. Median Age
  3. Encyclopedia of Keywords > Nature > Life > Relapse
  4. Range
  5. Atorvastatin
  6. Books about "Median Follow-Up" in Amazon.com

Book: Keywen Category Structure


  Short phrases about "Median Follow-Up"
  Originally created: April 04, 2011.
  Please send us comments and questions by this Online Form
  Please click on Move Up to move good phrases up.
0.0189 sec. a=1..